Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Eur Rev Med Pharmacol Sci ; 26(20): 7580-7593, 2022 10.
Article in English | MEDLINE | ID: mdl-36314330

ABSTRACT

OBJECTIVE: Polymerase ε exonuclease (POLE) is an enzyme involved in DNA replication and may be an attractive therapeutic target in various cancers. Here we sought to model the impact of specific POLE mutations on protein function. Due to the lack of a crystal structure, the tertiary structures of the wild type and four common mutants were modeled using I-Tasser server. MATERIALS AND METHODS: Molecular docking and dynamic simulation studies were performed, and the structure and function of the mutants analyzed through residue conservation analysis and protein folding energy changes. RESULTS: All mutants of POLE gene had favorable binding affinities compared with their wild type of counterpart. The P286R variant, but not the other variants, disrupted cladribine binding to the protein. Similarly, dynamics studies revealed instability of the P286R mutant, while V411L, L424V, and L424F appeared to favor cladribine binding. CONCLUSIONS: Since P286R is a hotspot mutation in endometrioid carcinomas, patients with this variant may not respond to cladribine. Population-based pharmacogenomics studies will be required to validate our results.


Subject(s)
Carcinoma, Endometrioid , DNA Polymerase II , Female , Humans , DNA Polymerase II/chemistry , DNA Polymerase II/genetics , DNA Polymerase II/metabolism , Cladribine/therapeutic use , Exonucleases/genetics , Molecular Docking Simulation , Mutation
2.
Eur Rev Med Pharmacol Sci ; 24(14): 7732-7744, 2020 07.
Article in English | MEDLINE | ID: mdl-32744700

ABSTRACT

OBJECTIVE: Familial hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease. While sarcomeric gene mutations explain many HCM cases, the genetic basis of about half of HCM cases remains elusive. Here we aimed to identify the gene causing HCM in a non-consanguineous Saudi Arabian family with affected family members and a history of sudden death. The impact of the identified mutation on protein structure and potential drug targets were evaluated in silico. MATERIALS AND METHODS: Triplets (two HCM subjects and one patent ductus arteriosus (PDA) case) and unaffected parents were screened by targeted next-generation sequencing (NGS) for 181 candidate cardiomyopathy genes. In silico structural and functional analyses, including protein modeling, structure prediction, drug screening, drug binding, and dynamic simulations were performed to explore the potential pathogenicity of the variant and to identify candidate drugs. RESULTS: A homozygous missense mutation in exon 1 of TMP1 (assembly GRCh37-chr15: 63340781; G>A) was identified in the triplets [two HCM and one patent ductus arteriosus (PDA)] that substituted glycine for arginine at codon 3 (p.Gly3Arg). The parents were heterozygous for the variant. The mutation was predicted to cause a significant and deleterious change in the TPM1 protein structure that slightly affected drug binding, stability, and conformation. In addition, we identified several putative TPM1-targeting drugs through structure-based in silico screening. CONCLUSIONS: TPM1 mutations are a common cause of HCM and other congenital heart defects. To date, TPM1 has not been associated with isolated PDA; to our knowledge, this is the first report of the homozygous missense variation p.Gly3Arg in TPM1 associated with familial autosomal recessive pediatric HCM and PDA. The identified candidate TPM1 inhibitors warrant further prospective investigation.


Subject(s)
Cardiomyopathy, Dilated/genetics , Ductus Arteriosus, Patent/genetics , Mutation, Missense , Triplets/genetics , Tropomyosin/genetics , Adult , Cardiomyopathy, Dilated/diagnosis , Cardiomyopathy, Dilated/drug therapy , Cardiomyopathy, Dilated/metabolism , Child , DNA Mutational Analysis , Ductus Arteriosus, Patent/diagnosis , Ductus Arteriosus, Patent/drug therapy , Ductus Arteriosus, Patent/metabolism , Female , Genetic Predisposition to Disease , Heredity , High-Throughput Nucleotide Sequencing , Homozygote , Humans , Male , Molecular Docking Simulation , Molecular Dynamics Simulation , Pedigree , Phenotype , Protein Binding , Protein Conformation , Protein Stability , Tropomyosin/metabolism , Young Adult
3.
Eur Rev Med Pharmacol Sci ; 23(4): 1710-1721, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30840296

ABSTRACT

OBJECTIVE: Pediatric familial dilated cardiomyopathy (DCM) is a rare and severe heart disease. The genetics of familial DCM are complex and include over 100 known disease-causing genes, but many causative genes are unknown. We aimed to identify the causative gene for DCM in a consanguineous Saudi Arabian family with affected family members and a history of sudden death. PATIENTS AND METHODS: Affected (two children) and unaffected (one sibling and the mother) family members were screened by next-generation sequencing (NGS) for 181 candidate DCM genes and underwent metabolic screening. Fifty-seven clinically annotated controls and 46 DCM cases were then tested for the identified mutation. In silico structural and functional analyses including protein modeling, structure prediction and dynamic simulations were performed. RESULTS: A homozygous missense mutation in exon 15 of the acyl-CoA dehydrogenase very long chain gene (ACADVL; chr17:7127303; G>A) was identified in affected subjects that substituted histidine for arginine at codon 450 (p.R450H). The variant was heterozygous in the mother and unaffected sister. The mutation was absent in 57 clinically annotated controls and 48 pediatric DCM cases. The mutation was predicted to cause a significant and deleterious change in the ACADVL protein structure that affected drug binding, stability, and conformation. Metabolic screening confirmed VLCAD deficiency in affected individuals. CONCLUSIONS: The ACADVL R450H mutation is an uncommon cause of the DCM phenotype that appears to be autosomal recessive. Targeted NGS is useful for identifying the causative mutation(s) in familial DCM of unknown genetic cause.


Subject(s)
Acyl-CoA Dehydrogenase, Long-Chain/genetics , Cardiomyopathy, Dilated/genetics , High-Throughput Nucleotide Sequencing , Homozygote , Sequence Analysis, DNA , Acyl-CoA Dehydrogenase, Long-Chain/chemistry , Acyl-CoA Dehydrogenase, Long-Chain/metabolism , Cardiomyopathy, Dilated/metabolism , Child , Computational Biology , Humans , Molecular Docking Simulation , Mutation, Missense , Thermodynamics
4.
Eur Rev Med Pharmacol Sci ; 20(1): 109-14, 2016.
Article in English | MEDLINE | ID: mdl-26813460

ABSTRACT

OBJECTIVE: Rheumatic heart disease (RHD) is a serious complication of rheumatic fever (RF). Plasma homocysteine (Hcy) levels are increased in RHD patients. MTHFR catalyzes the irreversible conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate and plays a vital role in Hcy metabolism. We hypothesize that the MTHFR C677T polymorphism is associated with a risk of RHD. PATIENTS AND METHODS: Eighty-six patients with RHD and 130 matched controls without a history of RHD were eligible for the study. The diagnosis of RHD was made according to modified Jones' criteria and echocardiography. Using echocardiography, RHD patients were further divided into mitral valve lesion (MVL) and combined valve lesion (CVL) groups. MTHFR C677T polymorphisms were genotyped by DNA sequencing. The chi-squared test was used to evaluate differences in genotypes. RESULTS: Control genotypes were in Hardy-Weinberg equilibrium. The C677T homozygous genotype (OR = 4.09; 95% CIs 1.16-14.44; p = 0.020) and recessive model (TT vs. CC+CT; OR = 4.05; 95% CIs 1.17-14.04; p = 0.019) were significantly associated with MVL RHD. CONCLUSIONS: This is the first study to investigate the association between the MTHFR C677T polymorphism and risk of RHD. The MTHFR C677T polymorphism is associated with RHD in patients with MVLs, perhaps via an Hcy-mediated cytokine effect.


Subject(s)
Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Mitral Valve , Rheumatic Heart Disease/genetics , Adult , Case-Control Studies , Genotype , Humans , Polymorphism, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL
...